Eterna Therapeutics (ERNA) - 2025 Q4 - Annual Report

Financial Condition - As of December 31, 2025, the company had an accumulated deficit of approximately $245.6 million[99]. - The company has incurred significant net losses since inception and expects to continue incurring losses for the foreseeable future[100]. - As of December 31, 2025, the company's stockholders' equity was approximately $2.4 million, and it completed a public offering in February 2026, raising net proceeds of about $9.5 million[127]. - The company may need to raise substantial additional capital to fund operations and execute its business strategy, with no assurance of obtaining it on favorable terms[93]. - The company may experience substantial dilution of existing stockholder ownership if additional capital is raised through equity or equity-linked securities[96]. - The company has not been profitable since commencing operations and may never achieve profitability, which could adversely impact its stock price and ability to raise capital[100]. Regulatory Risks - The regulatory approval process for the company's cellular therapy product candidates is uncertain and may be more expensive and time-consuming than for other therapeutic approaches[116]. - The FDA's evolving regulatory requirements for cellular therapy products may cause delays and increase costs for the company's product candidates[118]. - The regulatory approval processes by the FDA and comparable foreign authorities are lengthy and unpredictable, typically taking many years after clinical studies commence[141]. - If future product candidates do not receive regulatory approval, the company's business, prospects, and financial condition will be adversely affected[142]. - Delays in clinical studies can occur due to changes in regulatory requirements or unexpected events, potentially increasing costs and delaying development timelines[143]. - The FDA may impose clinical holds or require additional studies, which could further delay the approval process[144]. - Disruptions at the FDA due to funding shortages or other external factors could negatively impact the company's ability to obtain timely reviews and approvals[145]. - Regulatory agencies may impose limitations on approved product indications, which could affect commercialization efforts[140]. - The company may need to change regulatory strategies or modify applications, potentially delaying product development and approval[119]. Market Competition - The company faces intense competition from larger pharmaceutical and biotechnology firms, which may have more resources and could develop superior therapies[121]. - The company may face challenges in attracting and retaining highly qualified personnel, impacting its ability to implement its business strategy[113]. Intellectual Property Risks - The company relies heavily on in-licensed intellectual property from Factor Limited, with obligations including $0.2 million per month for the first twelve months and $0.1 million per month for the first nine months toward patent costs[101]. - The company has limited control over the maintenance and enforcement of rights it in-licenses, which could adversely affect its business[103]. - The company relies on maintaining intellectual property rights, and any failure in patent protection could allow competitors to develop similar products, adversely affecting profitability[158]. - The patent application process is expensive and time-consuming, and any defects in patent filings could result in invalid or unenforceable patents, impacting competitive advantage[160]. - The patent position of biotechnology and pharmaceutical companies is highly uncertain, with no consistent policy regarding the breadth of claims allowed in patents, leading to unpredictable outcomes in patent rights[163]. - The lifespan of a patent in the U.S. is generally 20 years from the earliest non-provisional filing date, and even if patents are obtained, they may expire before products are approved and commercialized[165]. - Patent term extensions under the Hatch-Waxman Amendments can provide up to five years of additional protection, but only one patent can be extended per approved product[166]. - Changes in patent law, such as the Leahy-Smith America Invents Act, have increased uncertainties and costs surrounding patent prosecution and enforcement[167]. - Recent court rulings have narrowed the scope of patent protection, creating further uncertainty regarding the validity and enforceability of patents[168]. - Protecting intellectual property rights globally is prohibitively expensive, and rights in some countries may be less extensive than in the U.S.[169]. - Foreign jurisdictions may not favor the enforcement of patents, making it difficult to stop infringement or marketing of competing products[170]. - Litigation to enforce patent rights can be costly and time-consuming, with no guarantee of success, potentially diverting resources from other business aspects[177]. - Adverse outcomes in litigation could result in patents being invalidated or interpreted narrowly, impacting the company's competitive position[178]. - The company may face claims regarding misappropriation of intellectual property from former employees or third parties, which could lead to costly litigation and loss of valuable rights[174]. - The company may face significant expenses and distractions due to ongoing litigation related to intellectual property claims, which could adversely affect its financial performance[179]. - Competitors with greater financial resources may sustain litigation costs more effectively, potentially impacting the company's competitive position in the marketplace[180]. Trademark Risks - The company relies on both registration and common law protection for its trademarks, which may be challenged or infringed, affecting brand recognition and market competitiveness[182]. - Proposed proprietary names for drug candidates must be approved by the FDA, and objections could require significant resources to identify suitable alternatives[183]. - The company may not be able to adequately protect its trademarks, which could lead to diminished goodwill and brand identity in the market[182]. - Trademark registration does not guarantee protection against infringement claims, and competitors may adopt similar names, causing market confusion[183]. - The company may incur additional costs if it needs to respond to trademark rejections or opposition proceedings[182]. - Legal proceedings could substantially increase operating losses and reduce resources available for development and marketing activities[179]. - The company may be liable for monetary damages if found to have willfully infringed a patent, which could further strain financial resources[179]. - The uncertainties from patent litigation could materially affect the company's ability to compete effectively in the marketplace[180]. Market Conditions - The company faces risks related to unstable market conditions, which may hinder its ability to raise additional capital[97]. - Legislative reforms, such as the Inflation Reduction Act, may impose price controls that could adversely affect revenue generation and profitability[151]. - The company faces risks from state-level regulations aimed at controlling pharmaceutical pricing, which may impact product commercialization[152]. - Future healthcare reforms may lead to reduced Medicare funding and lower reimbursement rates, affecting the pricing and demand for approved therapeutic products[153]. - The complexity of manufacturing biotechnology products may lead to production difficulties, impacting development timelines and costs[123].